It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



*Research Article* 1

# **Characterizing Longitudinal Antibody Responses in Recovered** <sup>2</sup> **Individuals Following COVID-19 Infection and Single-Dose** <sup>3</sup> **Vaccination in British Columbia, Canada: a Prospective Cohort** <sup>4</sup> **Study** 5

**Andrea D. Olmstead1,2#, Aidan M. Nikiforuk2,3#, Sydney Schwartz<sup>2</sup> , Ana Citlali Márquez<sup>2</sup> , Tahereh Valadbeigy<sup>2</sup> , Eri Flores<sup>2</sup> ,** 6 **Monika Saran<sup>1</sup> , David M. Goldfarb1,4, Althea Hayden<sup>5</sup> , Shazia Masud1,6, Agatha N. Jassem1,2, Muhammad Morshed1,2, Inna** 7 **Sekirov1,2\*** 8

- <sup>1</sup> Department of Pathology and Laboratory Medicine, University of British Columbia, 2211 Wesbrook Mall, Van- 10 couver, British Columbia, Canada, V6T 1Z7; andrea.olmstead@bccdc.ca,monikasaran@alumni.ubc.ca, [sha-](mailto:shazia.masud@fraserhealth.ca) 11 [zia.masud@fraserhealth.ca,](mailto:shazia.masud@fraserhealth.ca) [agatha.jassem@bccdc.ca,](mailto:agatha.jassem@bccdc.ca) [muhammad.morshed@bccdc.ca,](mailto:muhammad.morshed@bccdc.ca) inna.sekirov@bccdc.ca. 12
- <sup>2</sup> British Columbia Centre for Disease Control Public Health Laboratory, Provincial Health Services Authority, 655 13 West 12th Ave, Vancouver, British Columbia, Canada, V5Z 4R4 [; aidan.nikiforuk@bccdc.ca,](mailto:aidan.nikiforuk@bccdc.ca) [Syd-](mailto:Sydney.schwartz@bccdc.ca) 14 [ney.schwartz@bccdc.ca,](mailto:Sydney.schwartz@bccdc.ca) [citlali.marquez@bccdc.ca,](mailto:citlali.marquez@bccdc.ca) [tahereh.valadbeigy@phsa.ca,](mailto:tahereh.valadbeigy@phsa.ca) eri.flores@bccdc.ca. 15
- <sup>3</sup> School of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, British Colum- 16 bia, Canada, V6T 1Z3. 17
- <sup>4</sup> Department of Pathology and Laboratory Medicine, British Columbia Children's and Women's Hospital, 4500 18 Oak Street, Vancouver, British Columbia, Canada, V6H 3N1; David.Goldfarb@cw.bc.ca 19
- <sup>5</sup> Office of the Chief Medical Health Officer, Vancouver Coastal Health, Vancouver, BC, Canada; Althea.Hay- 20 den@vch.ca 21
- <sup>6</sup> Department of Pathology and Laboratory Medicine, Surrey Memorial Hospital, British Columbia, Canada. 22 These authors contributed equally to this work. 23
- **\*** Correspondence: Dr. Inna Sekirov (**MD,PhD**); email[: Inna.Sekirov@bccdc.ca](mailto:Inna.Sekirov@bccdc.ca) 24

## **Abstract:** 26

*Background:* Investigating antibody titres in individuals who have been both naturally infected with 27 SARS-CoV-2 and vaccinated can provide insight into antibody dynamics and correlates of protec- 28 tion over time. *Methods:* Human coronavirus (HCoV) IgG antibodies were measured longitudinally 29 in a prospective cohort of PCR-confirmed, COVID-19 recovered individuals (k=57) in British Co- 30 lumbia pre- and post-vaccination. SARS-CoV-2 and endemic HCoV antibodies were measured in 31 serum collected between Nov. 2020 and Sept. 2021 (n=341). Primary analysis used a linear mixed- 32 effects model to understand the effect of single dose vaccination on antibody concentrations adjust- 33 ing for biological sex, age, time from infection and vaccination. Secondary analysis investigated the 34 cumulative incidence of high SARS-CoV-2 anti-spike IgG seroreactivity equal to or greater than 5.5 35 log10 AU/mL up to 105 days post-vaccination. No re-infections were detected in vaccinated partic- 36 ipants, post-vaccination by qRT-PCR performed on self-collected nasopharyngeal specimens. 37

*Results:* Bivariate analysis (complete data for 42 participants, 270 samples over 472 days) found 38 SARS-CoV-2 spike and RBD antibodies increased 14-56 days post-vaccination (p<0.001) and vac- 39 cination prevented waning (B=1.66 [95%CI: 1.45-3.46]); while decline of nucleocapsid antibodies 40 over time was observed (B=-0.24 [95%CI: -1.2-(-0.12)]). A non-significant trend towards higher spike 41 antibodies against endemic beta-HCoVs was also noted. On average, SARS-CoV-2 anti-spike IgG 42 concentration increased in participants who received one vaccine dose by 2.06 log10 AU/mL 43 (95%CI: 1.45-3.46) adjusting for age, biological sex, and time. Cumulative incidence of high SARS- 44 CoV-2 spike antibodies (>5.5 log10 AU/mL) was 83% greater in vaccinated compared to unvac- 45 cinated individuals. *Conclusions:* Our study confirms that vaccination post-SARS-CoV-2 infection 46 tribution (CONOMEteThis prepsint reports mew research that has not been certified by peer review and should not be used to guide cimical practicey up to 85 47 days post-vaccination. 48

**Citation:** Lastname, F.; Lastname, F.; Lastname, F. Title. *Viruses* **2022**, *14*, x. https://doi.org/10.3390/xxxxx

Academic Editor: Firstname Lastname

Received: date Accepted: date Published: date

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Atativecommons.org/licenses/by/4.0/).



It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 2 of 20

**Keywords:** SARS-CoV-2; COVID-19; Cohort Study; Antibody Waning; IgG; Seroreactivity; 49 Hybrid Immunity; Fixed-Effect Models **50** South 30 South 30

## 51

## **1. Introduction** 52

The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel beta  $(β)$ - 53 coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused 54 significant morbidity, mortality, economic impact, and disruption of health care and so- 55 cietal systems. Prior to the emergence of COVID-19, four seasonal human coronaviruses 56 (HCoV) were identified that typically cause self-limited respiratory infections with mild 57 symptoms, i.e., the 'common cold' (1). Like SARS-CoV-2, HCoV-OC43, and HCoV- 58 HKU1 are β-coronaviruses, while HCoV-229E and HCoV-NL63 and classified as  $\alpha$ -coro- 59 naviruses (2). Coronavirus genera are separated by unique serological and genomic 60 characteristics; viral species from the same genus share cross-neutralizing (non-specific) 61 antibodies which arise from homology in viral genes and structural proteins (3). 62

In the province of British Columbia (BC), Canada, the first confirmed case of 63 COVID-19 was reported on January 25, 2020; strict and swift public health measures 64 were largely effective at controlling spread during the first wave, which peaked locally 65 between the third week of March and late April in 2020 (4). During the first epidemio- 66 logical wave of the pandemic, little was known about antibody responses to SARS-CoV- 67 2 infection and studies were needed to understand if and how quickly infected individu- 68 als develop a detectable, protective, and durable antibody-mediated immune response. 69 Understanding the durability or waning of antibodies over time helps elucidate the risk  $\frac{1}{20}$ of re-infection and inform vaccination schedules. Studies have shown that most SARS- 71 CoV-2 infected individuals seroconvert within 14-28 days; the spike (S) and the nucle- 72 ocapsid (N) proteins elicit the strongest humoral response (5, 6). Predictably, SARS-CoV- 73 2 antibody concentrations wane over time; the rate of decline varies widely depending 74 on various factors (e.g., age, biological sex, and disease severity) (7–9). Neutralizing anti- 75 bodies acquired naturally or from vaccination protect against infection and re-infection 76 (10). Several studies have shown a strong correlation between anti-S, anti-RBD and neu- 77 tralizing antibody titers, as such measuring anti-S and anti-RBD can be used as a proxy 78 for antibody-mediated protection (11–13). 79

Despite the success of SARS-CoV-2 vaccines, many individuals are still hesitant to 80 be immunized against COVID-19; supply shortages combined with social and economic 81 inequity hamper global vaccination efforts (14–16). The study of antibody dynamics fol- 82 lowing natural infection and the impact of vaccination on those who have been previ- 83 ously infected is needed, as novel SARS-CoV-2 variants with increasing capacity to es- 84 cape pre-existing immunity continue to evolve and spread (17–19). Observational stud- 85 ies agree that vaccination benefits those who have been previously infected, but the  $\sim$  86 number of doses required for optimal protection remains unclear (20–22). 87

We describe a prospective cohort that was established to monitor antibody re- 88 sponses over three months in people that recovered from SARS-CoV-2 infection. Many 89 participants were offered a single dose COVID-19 vaccine during the study; therefore, 90 we expanded the aims to study the dynamics of antibodies against both SARS-CoV-2, as 91 well as endemic HCoVs, in recovered individuals pre- and post-vaccination against 92 SARS-CoV-2, and investigated their relationship with age, biological sex, and symptom 93 duration. 94

95

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



## **2. Materials and Methods** 97

## *2.1. Study Design* 99

A prospective observational cohort termed CARE (Characterizing the Antibody 100 Response to Emerging COVID-19) was established from individuals who recovered 101 from SARS-CoV-2 infection, for the purposes of investigating antibody responses 102 against several SARS-CoV-2 epitopes (full spike (S), receptor binding domain (RBD) and 103 nucleocapsid (N)), as well as against the S protein of endemic HCoVs (OC43, HKU1, 104 NL63, 229E), at least 2 weeks post natural SARS-CoV-2 infection, with or without subse- 105 quent SARS-CoV-2 vaccination. Information on age, biological sex and date of PCR- di- 106 agnosis was collected through medical records, while information on the duration of 107 COVID-19 symptoms, hospitalization, and vaccination was collected through an online 108 self-reporting survey. The date of confirmed PCR diagnosis of SARS-CoV-2 infection 109 was used to estimate *'*days post-infection'. Survey data and participant informed con- 110 sent were collected and managed using REDCap electronic data capture tools hosted at 111 BC Children's Hospital (Vancouver, BC). REDCap (Research Electronic Data Capture) is 112 a secure, web-based application designed to support data capture for research studies 113 (23). Participants were enrolled in the cohort from November  $19<sup>th</sup>$ , 2020, to September  $7<sup>th</sup>$ , 114 2021. During this time the most prevalent SARS-CoV-2 variant in British Columbia tran- 115 sitioned between the Alpha, Beta, Gamma and Delta genotypes. The Beta variant was 116 detected in late 2020 and January 2021, increase prevalence of the Alpha variant shortly 117 followed and it remained dominant until June 2020. The Gamma variant was first de- 118 tected in late February 2021, it's incidence surpassed Alpha in July 2021. Public health 119 surveillance first recorded the Delta variant in March, and it was responsible for most 120 sequenced cases over the summer from July to September 2021(24). All data analysis 121 was performed in R version 4.0.4 using the packages: 'DataExplorer', 'survival', 'sur- 122 vminer', 'dplyr', 'ggfortify', 'tableone', 'naniar', 'RColorBrewer', 'lme4', 'mgcv', 123 'gam.check' and 'readr' (25). 124

## *2.2. Recruitment Criteria* 125

Adults 18 years of age and older from the greater Vancouver metropolitan area 127 were recruited if they had a confirmed PCR-positive SARS-CoV-2 infection and if they 128 were no longer required to self-isolate per the BC provincial public health guidelines 129 (i.e., tested positive for SARS-CoV-2 at least 14 days prior). The study protocol was ap- 130 proved by the University of British Columbia (UBC) Clinical Research Ethics Board 131 (H20-01089). 132

## *2.3. Sample Collection and Processing* 133

Participants were asked to donate blood samples collected by venipuncture (for 134 serological testing) and concurrent self-collected saline gargle samples (for SARS-CoV-2 135 real-time-polymerase chain reaction (PCR) testing), every two weeks for 3 months post- 136 recruitment (up to 7 collections total). Blood was drawn in gold-top serum separator 137 tube with polymer gel (BD, cat# 367989); after at least 30 minutes of clotting at room 138 temperature, the blood sample was then centrifuged at 1,400 G by staff at the collection 139 site and sent to the British Columbia Centre for Disease Control Public Health Labora- 140 tory (BCCDC PHL). At the BCCDC PHL the samples were divided into serum aliquots 141 that were frozen at −80°C within four hours of receipt. Blood collections occurred at four 142 sites in the Greater Vancouver Area, British Columbia Canada: BC Children's Hospital, 143 St. Paul's Hospital, Abbotsford Regional Hospital and Surrey Memorial Hospital. Saline 144 gargle samples were self-collected by the participants at home, in accordance with well- 145

- 126
- 

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 4 of 20

validated instructions (26), on the day of blood collection and transported to the BCCDC 146 PHL by the blood collection site. Self-collected saline gargle samples were tested for 147 SARS-CoV-2 by PCR. SARS-CoV-2 whole genome sequencing was done on a subset of 148 participants' SARS-CoV-2 positive diagnostic clinical specimens (27). All molecular, ge- 149 nomic, and serological testing (described below) for participant specimens was con- 150 ducted centrally at the BCCDC PHL. 151

## *2.4. Measurements of Humoral Immunity* 152

All serum samples were initially tested using a combination of three Health Can- 153 ada approved chemiluminescent immunoassays: 1) total antibodies to SARS-CoV-2 RBD 154 (Siemens SARS-CoV-2 Total Assay [COV2T]), 2) total antibodies to SARS-CoV-2 S (Or- 155 tho VITROSTM Anti-SARS-CoV-2 Total) and IgG anti-N antibodies (Abbott ARCHI- 156 TECT<sup>TM</sup> SARS-CoV-2 IgG), as per manufacturer guidelines, with results interpreted as  $157$ reactive or non-reactive using the manufacturer-recommended signal to cut-off ratios 158 (28, 29). All available samples were then tested using the V-PLEX COVID-19 Corona- 159 virus Panel 2 (IgG) (Mesoscale Diagnostics LLC (MSD): #K15369U), the diagnostic accu- 160 racy of the MSD assay was previously validated through comparison with alternative 161 Health Canada approved tests at the BCCDC PHL (30). The MSD assay provides quanti- 162 tative measures of IgG antibodies against RBD, S and N SARS-CoV-2 epitopes, as well as 163 IgG antibodies against S of the four seasonal HCoVs. Serological specimens were pro- 164 cessed as previously reported (30). Quantitative antibody levels expressed as log10 anti- 165 body units (AU)/ml were recorded and evaluated for all tested samples. MSD results 166 were interpreted as reactive or non-reactive using the MSD recommended signal thresh-<br>167 olds for serum: SARS-CoV-2 anti-S  $I_{\text{g}} = 1960$ ; anti-N  $I_{\text{g}} = 5000$ ; anti-RBD  $I_{\text{g}} = 538$ . 168 Cutoffs (derived at the BCCDC PHL) for seasonal HCoVs seropositive status are as fol- 169 lows: HCoV-229E anti-S IgG = 1700; HCoV-HKU1 anti-S IgG = 900; HCoV-NL63 anti-S 170  $I_{\text{g}} = 270$ ; HCoV-OC43 anti-S  $I_{\text{g}} = 2000$  (31). Samples were stratified by collection time 171 to  $\leq$  6 months and  $\geq$  6 months post infection and percent positivity was compared using 172 a Chi-square test  $(\chi^2$ test). 173

## *2.5. Power Analysis for Investigating Association between IgG Concentration and Vaccination* 174

A power calculation was conducted to determine the minimum number of paired 175 participant samples needed to estimate at least a 70% association between COVID-19 176 vaccination and HCoV anti-IgG antibody concentration. Antibody concentrations were 177 assumed to be normally distributed with a standard deviation of one. A significance 178 level of 5% and two-sided alternative were used (32). 179

## *2.6. Analytic Data Selection* 180

To analyze antibody dynamics, an analytic dataset was selected from the CARE 181 COVID-19 cohort. At least  $k = 18$  paired participant samples are required to estimate a 182 70% or greater association between COVID-19 vaccination and anti-HCoV IgG antibody 183 concentration. Exclusion criteria were applied to select an analytic dataset from  $k = 57$  184 participants with  $n = 341$  observations. One participant had no follow up samples and 185 was omitted from the analytic dataset  $(k = 1, n = 1)$ . Six participants were excluded because they were vaccinated before collection of their baseline sample  $(k = 6, n = 37)$ . Eight 187 participants were removed from the analytic dataset because of missing data in their 188 survey results  $(k = 8, n = 33)$ . After applying the exclusion criteria, the analytic dataset 189 contained  $k = 42$  participants with  $n = 270$  observations (Figure S1). There were  $k = 41$  190 participants with >1 pre-vaccine sample (n=210 pre-vaccine observations) used for analy- 191 sis of antibody waning pre-vaccination. 192

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### *2.7. Bivariate Data Analysis* 193

#### 2.7.1 Antibody Waning 195

Waning of SARS-CoV-2 antibodies prior to vaccination was investigated in inde- 196 pendent participant specimens measured at baseline using linear regression. HCoV anti- 197 IgG antibody signals at baseline were compared to signals 14-56 days post-vaccination 198 using a paired t-test in a sample of n=21 participants who received a COVID-19 vaccine 199 during the study. Waning of SARS-COV-2 specific IgG was measured prior to vaccina- 200 tion between participants using linear regression. Participant's baseline samples (de- 201 fined as the first specimen taken after enrolling in the study) were plotted for anti-S and 202 anti-N IgG over time. 203

#### 2.7.2 Descriptive statistics 205

Bivariate analysis was conducted between the exposure (a single dose of a Health 206 Canada approved COVID-19 vaccine) and outcome (SARS-CoV-2 anti-S or anti-N IgG) 207 of interest at baseline. Baseline represents the time of a participant's first blood draw 208 after enrollment. The bivariate relationship between vaccine status and covariates was 209 examined by t-test or chi square test depending on variable type. HCoV anti-IgG anti- 210 body signals were transformed to the logarithmic base ten scale for conformation to nor- 211 mality and ease of interpretation. 212

#### *2.8. Primary Analysis* 213

Primary analysis used a multivariable linear mixed-effects model to regress SARS- 214 CoV-2 anti-IgG concentration on vaccine status adjusting for dependency within partici- 215 pant samples and covariates defined as potential confounders by the common cause cri- 216 terion (33, 34). Separate models were fit for anti-S and anti-N IgG signals. Unconditional 217 mean models were used to find the intraclass correlation coefficient (ICC) before covari- 218 ates were added to build fixed effect models (35). Effect modification terms were as- 219 sessed by the Akaike information criterion and included in the fixed effect models to 220 understand if time from vaccination influences SARS-CoV-2 antibody concentrations 221 (36). 222

#### *2.9 Secondary Analysis* 223

Secondary analysis employed a Kaplan-Meier curve to estimate the cumulative in- 224 cidence of seroreactivity stratified by vaccine status. The survival function was trans- 225 formed to cumulative incidence by 1- $S(\tau)$  (37). Seroreactivity was defined from the dis- 226 tribution of SARS-CoV-2 anti-S IgG concentration at first blood draw (baseline); the  $95<sup>th</sup>$  227 percentile was chosen as the threshold  $(5.5 \log 10 \text{ AU/ml})$ . Participants were censored if 228 they were not seroreactive before loss to follow-up (right censoring). A log-rank test was 229 used to test the hypothesis that the cumulative incidence of seroreactivity between un- 230 vaccinated and vaccinated persons, who have been previously naturally infected with 231 SARS-CoV-2, does not differ (38). 232

#### **3. Results** 233

#### *3.1. CARE COVID-19 Cohort* 235

Fifty-seven individuals with COVID-19 were recruited through the CARE COVID- 236 19 Cohort. Subjects (17 male, 40 female; 18 to 76 years old) represented a range of 237 COVID-19 disease severity cases. Most subjects had a mild case of COVID-19, defined as 238

194

204

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 6 of 20

not requiring hospitalization; 6 reported being asymptomatic and 12 reported experienc- 239 ing fever. Only four subjects (7%) reported being hospitalized for COVID-19; one re- 240 quired intensive care. The observed case severity distribution was consistent with the 241 general distribution of COVID-19 disease severity in BC (~5% of diagnosed cases hospi- 242 talized as of April 2022) (39). 243

Participants were required to have recovered from COVID-19 (i.e., 10 days post- 244 PCR diagnosis) before providing their first blood and saline gargle sample. Collection 245 dates ranged from 18-490 days (median 152 days) since a positive PCR test (used as 246 proxy for time since infection), with the baseline collection date ranging from 18-339 247 days (median 114 days). Participants submitted between 1 and 7 samples, with approxi- 248 mately 2 weeks (median 14 days; range 7 –83 days) between each collection, with an av- 249 erage of 6 samples collected per participant and a total of 341 samples collected. No rein- 250 fections or persistent virus shedding were detected in self-collected saline gargle sam- 251 ples using RT-PCR (data not shown). 252

Virus whole genome sequencing was performed (27) on diagnostic samples from 253 14 participant specimens that were available for analysis, to determine the SARS-CoV-2 254 variant responsible for infection. SARS-CoV-2 variants were classified as ancestral (e.g., 255 A.1) (n=4) and the D614G mutant (e.g., B.1) (n=10), which is consistent with variants cir- 256 culating at the time of respective participants' diagnoses (40). Whole genome sequencing 257 data was missing for ~71% of participants and; therefore, not included as a covariate in 258 the analysis. Multiple studies corroborate no significant difference in neutralising anti- 259 bodies between the alpha variant and the ancestral isolate post mRNA vaccination with 260 BNT162b2 or mRNA-1273. Noteworthy reduction of post-vaccination neutralising sera 261 was observed for the beta variant in persons vaccinated with mRNA-1273(41). 262

## *3.2 Comparison of anti-SARS-CoV IgG Antibody Responses Across Four Commercial Assays* 263

All available samples (n=340; 1 missing) were initially tested using a combination of 264 three commercial serology assays supplied by Siemens (COV2T), Abbott (ARCHI- 265 TECT™), or Ortho (VITROS™) clinical diagnostics. Of 340 samples tested, 338 were clas- 266 sified as reactive using at least one assay (Table S1). All available samples (n=339) were 267 subsequently tested using a highly sensitive and multiplex electro chemiluminescent 268 assay offered by Meso Scale Diagnostics (MSD). Percent positivity differed across the 269 platforms and by antigenic target. Overall detection of anti-S was more sensitive than 270 anti-N SARS-CoV-2 IgG. Comparing anti-S results, the Ortho assay had the highest posi- 271 tivity rate (100%) followed by Siemens (95%) and MSD (89%) (Table S1). For anti-N re- 272 sults MSD (58%) outperformed Abbott (47%) with a 11% increase in positivity ( $\chi^2$ test, 273 P=0.01). When samples were stratified by collection time to less than or greater than 6 274 months post-infection, the anti-N positivity rate decreased for both the Abbott (72% to 275 13%) and MSD, (76% to 33%) (P<0.001). A 7% decline in positivity was observed for anti- 276 S (P=0.06) and 2% for anti-RBD (P=0.53) when tested by MSD (Table S1). Only antibody 277 measurements from the MSD assay were used in the multivariable analysis as the anti-S 278 IgG results compared well with Ortho and anti-N IgG results were superior to Abbott. 279

Waning of anti-S and anti-N IgG concentrations over time were measured between 280 participants using the first baseline observation for each of the k=42 participants in the 281 analytic dataset. Using linear regression analysis, overall waning was observed in both 282 anti-N and anti-S and the slope did not differ significantly across the two measures  $(P = 283)$ 0.46; Figure 1). On average SARS-CoV-2 antibodies wane at a rate of -0.0029 log10 284 AU/mL per day (P < 0.001) or  $\sim$  4228 AU/mL per month. These results confirm waning of 285 anti-SARS-CoV-2 antibodies over time in people who have recovered from natural 286 SARS-CoV-2 infection before vaccination. Estimates of anti-ARS-CoV-2 IgG waning are 287

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 7 of 20

calculated post-vaccination using a mixed-effects linear regression model and reported 288 as the 'primary analysis'. 289 *3.3 Serological Response to SARS-CoV-2 Vaccination* 290 Bivariate analysis was conducted on the analytic dataset to compare participant 291 antibody responses pre- and post-vaccination for COVID-19. Participant's serology re- 292 sults and survey responses are summarized and stratified at baseline by the exposure of 293 interest, one dose of a COVID-19 vaccine (Table 1). No difference in the distribution of 294 covariates between participants who received and did not receive a COVID-19 vaccine 295 over the study period was observed for all variables except the number of participant 296 visits. Though follow-up time did not significantly differ between the two groups, on 297 average unvaccinated participants were observed 0.95 (approximately one) fewer times 298 than those who received a COVID-19 vaccine (P=0.014) (Table 1). Importantly, age, bio-<br>299 logical sex, days from positive PCR test (diagnosis), symptom duration and endemic 300 anti-coronavirus IgG signals did not differ by exposure at baseline; therefore, we expect 301 limited confounding from these covariates when estimating the association between 302 COVID-19 vaccination and anti-SARS-CoV-2 IgG signals. Covariates, which met the def- 303 inition of a confounder by the common cause criteria, were adjusted for in the primary 304 analysis using a linear mixed effects model. 305

In k=21 paired participants, SARS-CoV-2 anti-S and anti-RBD IgG antibody concen- 306 trations increased post vaccination by 1.63 ( $P<0.001$ ) and 1.82 ( $P<0.001$ ) log10 AU/ml 307 (Figure 2A & 2B). Anti-N antibody concentration continued to decrease post vaccination 308 by -0.3 (P=0.03) log10 AU/ml (Figure 2C), consistent with waning observed prior to vac- 309 cination. Most participants (>99%) were found to be seropositive for anti-S antibodies 310 against the endemic HCoVs. Post vaccination, anti-S antibody concentrations for en- 311 demic human ®-coronaviruses HCoV-HKU1 and HCoV-OC43 slightly increased (P=0.11 312 and  $P=0.07$ ) (Figure 3B & 3D). No increase in antibody concentration was observed for 313 the endemic human  $\Phi$ -coronaviruses HCoV-229E and HCoV-NL63 (P=0.43 and P=0.67) 314 (Figure 3A & 3C).  $315$ 

## *3.4 Primary Analysis* 316

Linear mixed-effects regression models were used to estimate intraclass correlation 317 within participant samples and the relationship between COVID-19 vaccination and 318 SARS-CoV-2 anti-S or anti-N IgG antibody concentration. An unconditional mean model 319 was fit to partition within participant variation from between participant variation (Ta- 320 ble 2). The minority of variation in SARS-CoV-2 anti-S IgG concentration was attributa- 321 ble to differences between participants (ICC=0.43) (Table 2). On average, anti-S IgG con- 322 centration increased over time in participants who received one dose of a COVID-19 323 vaccine during the study by 2.06 log10 AU/mL (95%CI: 1.45-3.46) adjusting for age, bio- 324 logical sex, days from positive PCR test (time) and effect modification between COVID- 325 19 vaccination and time (Table 2). In the adjusted model, the ICC increased to 0.89 indi- 326 cating that between participant differences (e.g., COVID-19 vaccination) explains most 327 of the variation in SASRS-CoV-2 anti-S IgG antibody concentration. COVID-19 vaccina- 328 tion has a positive association with SARS-CoV-2 anti-S IgG antibody concentration, 329 which increases over time. Variation in anti-N IgG concentration was due to differences 330 between participants in the unconditional mean model (ICC=0.88). The average, anti-N  $331$ IgG concentration decreased in vaccinated participants over time 332 (-0.243 log10 AU/mL, 95%CI: -1.2 – [=0.12]) adjusting for age, biological sex, days from 333 positive PCR test (time) and effect modification between COVID-19 vaccination and 334 time (Table 2). Variation in anti-N IgG concentration after fitting the adjusted model was 335 explained by within participant variance (ICC=30). Overall, these results indicate that 336 waning of SARS-CoV-2 anti-N IgG is unaffected by COVID-19 vaccination. Anti- S IgG 337

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 8 of 20

titers increase post vaccination; therefore, vaccination of recovered individuals benefits 338 the durability of their humoral immune response.  $339$ 

#### *3.5 Secondary Analysis* 340

Secondary analysis used the Kaplan-Meier method to estimate the cumulative inci- 341 dence of seroreactivity above a defined threshold in vaccinated and unvaccinated partic- 342 ipants over time. Seroreactive status was classified by the threshold of  $\geq$  5.5 log10 343 AU/mL SARS-CoV-2 anti-S IgG, as described in Methods. Participants with antibody 344 measurements equal to or greater than the threshold were considered reactive. Over the 345 105 days follow up from baseline (first antibody measurement available for participants 346 post-infection), 88% (95%CI: 42-98%) of vaccinated participants (n=16) were seroreactive 347 compared to 5% (95%CI: 0-14%) of unvaccinated participants (n=1) (P= 0.03) (Figure 4).  $348$ A single dose of COVID-19 vaccine increases the probability of a SARS-CoV-2 anti-S IgG 349 antibody concentration  $\geq 5.5 \log 10 \text{ AU/mL}$  by 83%. 350



**Figure 1. Longitudinal decay of SARS-CoV-2 anti-N and anti-S IgG concentration over time in natural SARS-CoV-** 352 **2 infected CARE participants prior to vaccination (k= 42, n= 42 samples).** Participant samples were restricted to the 353 first collection date (baseline) and plotted independently. Linear regression was used to estimate the decrease in anti-S 354 and anti-N titre over time since PCR test result.  $355$ 

- 356
- 357
	- 358
	- 359
- 360
- 361
- 362
- 
- 363

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 9 of 20

364



**Table 1.** Descriptive statistics of study participants at the beginning of the study (baseline) in the analytic dataset with 365



#### It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 10 of 20



\$Participants are stratified by vaccine status (primary exposure) throughout the study period, n=21 participants were 367 vaccinated while under observation. Bivariate associations at baseline were examined by testing for a difference in the 368 distribution of covariates between participants who did or did not receive one dose of a COVID-19 vaccine over the 369 study period. 2370

\*p-values are reported for parametric tests used for continuous (t-test) and categorical variables ( $\chi^2$ test). 371

- 373
- 374
- 375
	-
	- 376
		-
		- 377
		- 378
		-
		- 379
		- 380
			- - 381
				- 382
				- 383
			- 384

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2022.09.28.22280429;](https://doi.org/10.1101/2022.09.28.22280429) this version posted September 29, 2022. The copyright holder for this

*Viruses* 2022, 14, x FOR PEER REVIEW 11 of 20



385



**Figure 2. SARS-CoV-2 anti-IgG pre- and post-vaccination.** Antibody signals in k=21 paired participants, who re- 386 ceived a COVID-19 vaccine during the study, at baseline and 14 to 56 days post-vaccination, presented by individual 387 SARS-CoV-2 antigen (k=21): **A)** anti-S, **B)** anti-RBD, **C)** anti-N. Differences in antibody signals were examined with a 388 paired t-test. 389



**Figure 3. Endemic human coronavirus anti-S IgG antibody signals pre- and post-vaccination.** HCoV antibody sig- 391 nals in n=21 paired participants, who received a COVID-19 vaccine during the study, measured at baseline (before 392 vaccination) and 14 to 56 days post-vaccination, presented by HCoV species: **A)** HCoV-229E anti-Spike (S), **B)** HCoV- 393 HKU1 anti-S, **C)** HCoV-NL63 anti-S, **D)** HCoV-OC43 anti-S. Difference in antibody signal was examined with a paired 394 t-test. 395

396

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 12 of 20

**Table 2.** Summary of linear mixed effects models fit to examine the relationship between anti-S IgG log10 AU/ml 399 (light grey) or anti-N IgG log10 AU/ml (dark grey) and COVID-19 vaccination status adjusting for: biological sex, age, 400

**Unconditional Mean Model (S) Intraclass Correlation Coefficient** Participant ID  $(n=42)$  | 0.434 Residual 0.566 Random Intercept Model **Variable Fixed Effect Estimate 95%CI** *Anti-Spike IgG* **Intercept** 4.84 3.27-6.39 **Vaccine-Yes** 0.40  $-0.41-1.20$ **Biological Sex-Male**  $\begin{array}{|c|c|c|} \hline 0.93 & 0.068-1.79 \hline \end{array}$ **Age (Years)**  $-0.029$   $-0.063-0.0057$ **Time from +ve PCR Test<sup>a</sup>** -0.20 -0.47-0.054 **Vaccine: Time<sup>a</sup>** 1.86 1.39-2.21 **Random Effects Intraclass Correlation Coefficient** 0.893 **Unconditional Mean Model (N)** Participant ID (n=42) 0.875 Residual 0.125 **Random Intercept Model Variable | Variable | Fixed Effect Estimate 95%CI** *Anti-Nucleocapsid IgG* **Intercept** 3.14 2.48-3.79 **Vaccine-Yes**  $\vert$  -0.080  $\vert$  -0.42-0.26 **Biological Sex-Male**  $\begin{array}{|c|c|c|c|c|c|} \hline 0.27 & -0.095-0.63 \hline \end{array}$ **Age (Years)** 0.016 0.0017-0.03 **Time from +ve PCR Test<sup>a</sup>**  $-0.40$   $-0.53-(-0.27)$ 

and time from clinical diagnosis. 401

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 13 of 20



\*An effect modification term was incorporated to explore how the effect of vaccination on antibody concentration dif- 402 fers by time since diagnosis with a PCR test. Unconditional means models were fit to partition the variance by partici- 403 pant without inclusion of other exposure variables. Fixed effect models were built by applying the common cause cri- 404 terion to select covariates which are a cause of the exposure, outcome, or both. 405

- 406
- 407
- 408
- 409
- 410
- 411
	-
	-

412

- 413
- 414
- 

- - 416
		- 417
		- 418

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 14 of 20



419

**Figure 4. Cumulative incidence of seroreactivity (> 5.5 SARS-CoV-2 anti-S IgG Log10 AU/mL) days from partici-** 420 **pant's first blood draw at baseline, stratified by vaccination status over the study period.** Vaccinated participants 421 achieved antibody titres not possible from natural infection alone (unvaccinated participants). Within 105 days of follow 422 up, 88% (95%CI: 42-98%) of vaccinated participants were seropositive, an increase of 83% in comparison to the unvac- 423 cinated group (P= 0.03). In previously naturally infected individuals, COVID-19 vaccination increases SARS-CoV-2 anti- 424 S IgG concentration over time to levels which are not attained by natural infection alone. No re-infections were detected 425 by qRT-PCR in the vaccinated or unvaccinated group during the study period, specimens were self-collected. 426

427

428

429

430

431

432

433

434

435

436

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### **4. Discussion** 438

#### *4.1. Summary of Results* 439

A prospective cohort study was carried out in British Columbia to observe anti- 440 SARS-CoV-2 and anti-endemic HCoV antibody dynamics in participants who were in- 441 fected with SARS-CoV-2, a subset received the first dose of a Health Canada approved 442 SARS-CoV-2 vaccine during the follow up. Several commercial serology assays were 443 used to detect anti-Coronavirus antibodies; detection of anti-SARS-CoV-2 antibodies 444 was confirmed in all available samples, although both anti-S and anti-N antibodies de- 445 clines over time post-infection. Bivariate analysis found that vaccination significantly 446 increased the titer of SARS-CoV-2 anti-S IgG antibodies 14-56 days post vaccination; no 447 significant association was found between SARS-CoV-2 vaccination and endemic HCoV 448 anti-S IgG antibodies, although antibodies against the S protein of beta-coronaviruses 449 trended upwards, unlike those against the S protein of alpha-coronaviruses. Vaccination 450 was not observed to boost SARS-CoV-2 anti-N IgG titers, which waned overtime in both 451 vaccinated and unvaccinated individuals. The rate of anti-N waning was approximately 452 double that of anti-S. Secondary analysis used a Kaplan-Meier model to estimate the cu- 453 mulative incidence of anti-S antibody titers equal to or above 5.5 log10 AU/mL ('sero- 454 reactivity threshold') in those vaccinated and unvaccinated. In the vaccinated group, 455 88% (95%CI: 42-98%) of participants had SARS-CoV-2 anti-S IgG titers greater than or 456 equal to this threshold, while this level was achieved in only one unvaccinated partici- 457 pant measured twenty-seven days post infection. 458

Despite overall antibody waning in unvaccinated participants, a few substantial 459 increases in antibody levels were observed. No reinfections were confirmed using qRT- 460 PCR in self-collected saline gargle samples throughout the study, however one partici- 461 pant had a large ( $\geq 8$ -fold) average increase in mean antibody levels (anti-S, RBD and N  $462$ IgG) seven months following initial SARS-CoV-2 diagnosis, which may be explained by 463 a second exposure to SARS-CoV-2. A second participant had 6-fold increase of anti-S  $464$ and anti-RBD levels, but not anti-N IgG levels, suggesting they may also have been re- 465 exposed. Other detected increases in antibody levels were of much smaller magnitude 466 and might be secondary to rising titers early in convalescence or be explained by tech- $467$ nical variations rather than a biological mechanism. 468

#### *4.2. Comparison with Literature* 470

Previous studies have measured changes in SARS-CoV-2 antibody titers over time. 471 Repeated exposure to SARS-CoV-2 antigens increases IgG titer, while antibodies gener- 472 ated from a single exposure wane overtime (42, 43). Following infection, SARS-CoV-2 473 specific antibody waning has been observed to decrease from the  $8<sup>th</sup>$  to  $9<sup>th</sup>$  week post 474 symptoms onset, with detectable levels observed up to the end of the  $12<sup>th</sup>$  week (44). In 475 those with multiple SARS-CoV-2 exposures or a hybrid immune response from infection 476 and vaccination, decrease of antibody titers stops shortly after the secondary antigen 477 exposure when stimulation of the memory B cell response produces additional antibod- 478 ies (45). A strong correlation between total lymphocyte count and SARS-CoV-2 anti-S 479 IgG provides evidence that an ongoing/active immune response provides better protec- 480 tion than a dormant one (44). Waning of SARS-CoV-2 antibodies differs by their para- 481 tope, anti-N IgG antibodies wane faster than anti-S. The difference in reactivity between 482 anti-N to anti-S IgG was observed at the population level, anti-N seroprevalence under- 483 estimated the number of confirmed infections by 9-31% (46). Vaccination post SARS- 484 CoV-2 infection prevents waning of anti-S but has no effect on anti-N IgG (47). Hybrid 485 immunity also benefits the breadth of the antibody mediated response, increasing the 486 probability that existing antibodies are effective against the novel variants. Persons who 487

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 16 of 20

were infected prior to receiving one of two doses of a COVID-19 vaccine had more so- 488 matic mutations and antibody production from the IGHV2-5; IGHJ4-1 germline which 489 was not active in the vaccinated but uninfected (48, 49). Additionally, hybrid immunity 490 produces greater total and neutralizing anti-S titers than natural infection or vaccination 491 alone (45). Our study both supports and builds upon prior findings, as we show that 492 SARS-CoV-2 IgG antibodies wane in SARS-CoV-2 infected people over time, with the 493 rate of decline being greater for anti-N IgG than anti-S; vaccination post-infection boosts 494 anti-S IgG titers and participants with hybrid immunity possess anti-S antibody levels 495 which are not common in those infected but unvaccinated. Our calculated rate of anti-496 body decline may be used to help estimate infection timing in seroprevalence studies. 497

## *4.3. Clinical and Epidemiological Interpretation* 498

Our findings have important implications for clinical practice and public health 499 guidelines as the pandemic progresses into its third year, novel viral variants continue to 500 emerge, and vaccine doses are more widely distributed globally. Humoral immunity 501 from natural infection wanes and vaccination with at least one dose of COVID-19 vac- 502 cine increases SARS-CoV-2 anti-S IgG titers immediately and over time. Therefore, we 503 recommend that naturally infected individuals receive COVID-19 vaccination to increase 504 protection from re-infection and severe disease and the duration of their humoral im- 505 mune response against SARS-CoV-2. We demonstrate that a single dose of SARS-CoV-2 506 vaccine is effective in boosting anti-S antibody titers to high levels, which has implica- 507 tions in distribution of vaccine supplies in those countries with scarce access and low 508 vaccination levels in the setting of high numbers of natural infection. 509

#### *4.4 Strengths and Limitations* 510

The strength of the described study stems from the prospective design, use of mul-<br>511 tiple serological tests, including the quantitative MSD option, and thorough analysis.  $A = 512$ prospective cohort design offers several benefits, which allowed us to observe SARS- 513 CoV-2 antibody dynamics over time with minimal bias. Recruiting participants post- 514 infection but prior to vaccination delineated the sequence of temporal events, limiting 515 the probability that any changes in antibody titers observed post-vaccination were due 516 to causes other than the vaccine. Selection bias was minimized as the participants expo- 517 sure and outcome status were not known when they were recruited into the study. At 518 the beginning of the study, the measured covariates were exchangeable between partici- 519 pants who were unvaccinated or vaccinated during follow-up. Balance of the covariates 520 allowed for estimation of the relationship between vaccination and anti-SARS-CoV-2 521 IgG antibody titer with minimal bias from confounding. Utilizing multiple serological 522 tests strengthened our observations, as well as allows generalizability to study popula- 523 tions in many different laboratories. Statistical power was optimized by analysis with a 524 mixed effects linear regression model, which accommodated multiple repeated 525 measures per participant. 526

Limitations of the work include differential loss to follow up in the vaccinated and 527 unvaccinated groups, a small sample size, and incomplete/missing survey responses. 528 Unvaccinated participants were observed to have approximately one fewer visit than 529 those who received a COVID-19 vaccine. Vaccines were not an originally planned inter- 530 vention in the study and were made available in British Columbia on a stage roll-out 531 basis about half-way through the study period. The difference in visit numbers between 532 the vaccinated and unvaccinated groups is likely related to surveillance bias- those who 533 receive a medical intervention are more open to clinical follow up than those who do 534 not. Obtaining a larger sample size initially planned for the study was difficult due to 535 low enrollment uptake, likely related to the social and economic stress of the pandemic 536

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 17 of 20

on the public and geographic limitations on recruitment related to the availability of 537 sample collection sites. 538

While the reached sample size was adequate for the primary analysis- which in- 539 cluded repeated measures- enrolling additional participants would have allowed for a 540 more precise estimate of the relationship between COVID-19 vaccination and endemic 541 HCoVs anti-IgG titers. Although not significant, a trend was observed for increased av- 542 erage antibody titers for HCoV-HKU1 and HCoV-OC43 following vaccination which, 543 like SARS-CoV-2, are both β-coronaviruses in contrast to decreases in the averages ob-  $544$ served for both HCoV-NL63 and HCoV-229E which are  $\alpha$ -coronaviruses. The study de- 545 sign may have also underestimated any association between existing endemic corona- 546 virus IgG titers and COVID-19 vaccination as the sample was restricted to persons previ- 547 ously infected with SARS-CoV-2. COVID-19 has been shown to affect endemic corona- 548 virus antibody levels and as such, the effect of vaccination should be observed in a co- 549 hort of SARS-CoV-2 naive persons prior to vaccination (50–52). The overall effect of 550 SARS-CoV-2 vaccination and/or infection on the circulating antibodies against endemic 551 HCoVs in the population may have implications for their seasonal epidemiology. 552

#### **5. Conclusions** 553

In summary, we report that single dose vaccination in a British Columbia-based 554 cohort after natural infection significantly increases SARS-CoV-2 anti-S IgG titer by 1.63 555  $log<sub>10</sub>$  units and that vaccination increases the durability of high anti-S titers over time.  $556$ Vaccination post-natural infection had no significant association with SARS-CoV-2 anti- 557 N IgG titer; a non-significant trend towards higher anti-S IgG against the endemic  $β$ - 558 HCoVs was observed. Our results provide support that vaccination is beneficial for 559 achieving higher and more persistent SARS-CoV-2 anti-S IgG levels. We also report an 560 estimated rate of decay of anti-N antibodies, which may be useful for ongoing popula- 561 tion seroprevalence estimates. Future studies should examine the impact of infection 562 following vaccination on antibody dynamics, as vaccine breakthrough infections with 563 omicron or other variants continue to occur. 564

**Supplementary Materials:** The following supporting information can be downloaded at: 565 www.mdpi.com/xxx/s1, Table S1: Summary of serological test results; Figure S1: Exclusion criteria 566 were applied to select an analytic data of  $n = 270$  observations from  $k = 42$  dependent participants 567 (clusters). 568

**Author Contributions:** "Conceptualization, **A.D.O**, **A.N.J, M.M** and **I.S**.; methodology, **A.M.N,** 569 **A.C.M**,**E.F, M.S, A.H** and **S.M**; software, **A.D.O, A.M.N**; formal analysis, **A.D.O, A.M.N**; investiga- 570 tion, **A.D.O, I.S**; resources, **A.D.O**, **A.N.J, M.M**, **I.S, A.C.M**, **E.F, M.S, A.H** and **S.M**; data curation, 571 **S.S**, **A.C.M** and **T.H**; writing—original draft preparation, **A.D.O, A.M.N**; writing—review and ed- 572 iting, **All Authors**; visualization, **A.D.O**, **A.M.N**; supervision, **A.N.J and I.S**; project administration, 573 **A.C.M**, **E.F**, **A.H**, ; funding acquisition, **A.N.J, M.M** and **I.S**.. All authors have read and agreed to 574 the published version of the manuscript.  $575$ 

**Funding:** This study was funded by Genome BC's COVID-19 Rapid Response Funding Program 576 (#COV-050). 577

**Institutional Review Board Statement:** The study was conducted in accordance with the Declara- 578 tion of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of The Uni- 579 versity of British Columbia (H20-01089 on 4/21/2020). 580

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the 581 study. 582

**Data Availability Statement:** The datasets generated during and/or analyzed during the current 584 study are available from the corresponding author on reasonable request. 585

586

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 18 of 20

597

**Acknowledgments:** We thank the dedicated staff at the BCCDC PHL for processing, testing, and 587 sequencing clinical specimens. We also thank all the study participants who volunteered their time 588 and specimens for this research. We also are thankful to all the staff who helped to collect and process 589 samples for this study at Abbotsford Regional Hospital, Surrey Memorial Hospital and St. Paul's 590 Hospital. Notably, we thank the staff at BC Children's Hospital for providing extra guidance and 591 support to the researchers in conducting the study.  $592$ 

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the 593 design of the study; in the collection, analyses, or interpretation of data; in the writing of the manu- 594 script; or in the decision to publish the results.  $595$ 

#### **References** 596

1. Fung TS, Liu DiX. 2021. Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. 598 https://doi.org/101146/annurev-micro-110520-023212 75:19–47. 599

2. Fehr AR, Perlman S. 2015. Coronaviruses: An Overview of Their Replication and Pathogenesis. Coronaviruses: Methods 600 and Protocols 1282:1–23. 601

3. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, Borgert BA, Moreno CA, Solomon 602 BD, Trimmer-Smith L, Etienne V, Rodriguez-Barraquer I, Lessler J, Salje H, Burke DS, Wesolowski A, Cummings DAT. 2020. A 603 systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with 604 severity. Nature Communications 2020 11:1 11:1–16. 605

4. Skowronski DM, Sekirov I, Sabaiduc S, Zou M, Morshed M, Lawrence D, Smolina K, Ahmed MA, Galanis E, Fraser MN, 606 Singal M, Naus M, Patrick DM, Kaweski SE, Mill C, Reyes RC, Kelly MT, Levett PN, Petric M, Henry B, Krajden M. 2020. Low 607 SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Co- 608 lumbia, Canada, March-May 2020. medRxiv 2020.07.13.20153148. 609

5. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, Liao P, Qiu JF, Lin Y, Cai XF, Wang DQ, Hu Y, Ren JH, Tang N, 610 Xu YY, Yu LH, Mo Z, Gong F, Zhang XL, Tian WG, Hu L, Zhang XX, Xiang JL, Du HX, Liu HW, Lang CH, Luo XH, Wu SB, Cui 611 XP, Zhou Z, Zhu MM, Wang J, Xue CJ, Li XF, Wang L, Li ZJ, Wang K, Niu CC, Yang QJ, Tang XJ, Zhang Y, Liu XM, Li JJ, Zhang 612 DC, Zhang F, Liu P, Yuan J, Li Q, Hu JL, Chen J, Huang AL. 2020. Antibody responses to SARS-CoV-2 in patients with COVID- 613 19. Nature Medicine 2020 26:6 26:845–848. 614

6. To KKW, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, Yip CCY, Cai JP, Chan JMC, Chik TSH, Lau DPL, Choi 615 CYC, Chen LL, Chan WM, Chan KH, Ip JD, Ng ACK, Poon RWS, Luo CT, Cheng VCC, Chan JFW, Hung IFN, Chen Z, Chen H, 616 Yuen KY. 2020. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during 617 infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 20:565–574. 618

7. Dorigatti I, Lavezzo E, Manuto L, Ciavarella C, Pacenti M, Boldrin C, Cattai M, Saluzzo F, Franchin E, Del Vecchio C, 619 Caldart F, Castelli G, Nicoletti M, Nieddu E, Salvadoretti E, Labella B, Fava L, Guglielmo S, Fascina M, Grazioli M, Alvisi G, 620 Vanuzzo MC, Zupo T, Calandrin R, Lisi V, Rossi L, Castagliuolo I, Merigliano S, Unwin HJT, Plebani M, Padoan A, Brazzale 621 AR, Toppo S, Ferguson NM, Donnelly CA, Crisanti A. 2021. SARS-CoV-2 antibody dynamics and transmission from commu- 622 nity-wide serological testing in the Italian municipality of Vo'. Nature Communications 2021 12:1 12:1–11. 623

8. Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, Hauser BM, Caradonna TM, Clayton KL, 624 Nitido AD, Murali MR, Alter G, Charles RC, Dighe A, Branda JA, Lennerz JK, Lingwood D, Schmidt AG, Iafrate AJ, Balazs AB. 625 2021. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 184:476-488.e11. 626

9. Noh JY, Kwak JE, Yang JS, Hwang SY, Yoon JG, Seong H, Hyun H, Lim CS, Yoon SY, Ryou J, Lee JY, Kim SS, Park SH, 627 Cheong HJ, Kim WJ, Shin EC, Song JY. 2021. Longitudinal Assessment of Antisevere Acute Respiratory Syndrome Coronavirus 628 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019. J Infect Dis 224:754–763. 629

10. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. 630 2021. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature 631 Medicine 2021 27:7 27:1205–1211. 632

11. Dolscheid-Pommerich R, Bartok E, Renn M, Kümmerer BM, Schulte B, Schmithausen RM, Stoffel-Wagner B, Streeck H, 633 Saschenbrecker S, Steinhagen K, Hartmann G. 2022. Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neu- 634 tralization activity. J Med Virol 94:388–392. 635

12. Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, Hauser BM, Caradonna TM, Clayton KL, 636 Nitido AD, Murali MR, Alter G, Charles RC, Dighe A, Branda JA, Lennerz JK, Lingwood D, Schmidt AG, Iafrate AJ, Balazs AB. 637 2021. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 184:476-488.e11. 638

13. Dogan M, Kozhaya L, Placek L, Gunter C, Yigit M, Hardy R, Plassmeyer M, Coatney P, Lillard K, Bukhari Z, Kleinberg 639 M, Hayes C, Arditi M, Klapper E, Merin N, Liang BTT, Gupta R, Alpan O, Unutmaz D. 2021. SARS-CoV-2 specific antibody 640 and neutralization assays reveal the wide range of the humoral immune response to virus. Communications Biology 2021 4:1 641 4:1–13. 642

14. Solís Arce JS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, Syunyaev G, Malik AA, Aboutajdine S, Adeojo 643 O, Anigo D, Armand A, Asad S, Atyera M, Augsburg B, Awasthi M, Ayesiga GE, Bancalari A, Björkman Nyqvist M, Borisova 644

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### *Viruses* **2022**, *14*, x FOR PEER REVIEW 19 of 20

E, Bosancianu CM, Cabra García MR, Cheema A, Collins E, Cuccaro F, Farooqi AZ, Fatima T, Fracchia M, Galindo Soria ML, 645 Guariso A, Hasanain A, Jaramillo S, Kallon S, Kamwesigye A, Kharel A, Kreps S, Levine M, Littman R, Malik M, Manirabaruta 646 G, Mfura JLH, Momoh F, Mucauque A, Mussa I, Nsabimana JA, Obara I, Otálora MJ, Ouédraogo BW, Pare TB, Platas MR, 647 Polanco L, Qureshi JA, Raheem M, Ramakrishna V, Rendrá I, Shah T, Shaked SE, Shapiro JN, Svensson J, Tariq A, Tchibozo 648 AM, Tiwana HA, Trivedi B, Vernot C, Vicente PC, Weissinger LB, Zafar B, Zhang B, Karlan D, Callen M, Teachout M, Hum- 649 phreys M, Mobarak AM, Omer SB. 2021. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. 650 Nature Medicine 2021 27:8 27:1385–1394. 651

15. Padma T V. 2021. COVID vaccines to reach poorest countries in 2023 - despite recent pledges. Nature 595:342–343. 652

16. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, Giattino C, Rodés-Guirao L. 2021. A global database 653 of COVID-19 vaccinations. Nat Hum Behav 5:947–953. 654

17. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW. 2021. The biological and 655 clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics 2021 22:12 22:757–773. 656

18. Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland W-H, Porrot F, Staropoli I, Lem- 657 oine F, Péré H, Veyer D, Puech J, Rodary J, Baele G, Dellicour S, Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina 658 -Bokalanga T, Martí-Carreras J, Cuypers L, Sève A, Hocqueloux L, Prazuck T, Rey F, Simon-Loriere E, Bruel T, Mouquet H, 659 André E, Schwartz O. 2021. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 2021 1–7. 660

19. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, Myers 661 R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown KE, Hopkins S, Chand M, Ramsay M. 2021. Effectiveness 662 of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. NEJM 385:585–594. 663

20. Sokal A, Barba-Spaeth G, Fernández I, Broketa M, Azzaoui I, de La Selle A, Vandenberghe A, Fourati S, Roeser A, Meola 664 A, Bouvier-Alias M, Crickx E, Languille L, Michel M, Godeau B, Gallien S, Melica G, Nguyen Y, Zarrouk V, Canoui-Poitrine F, 665 Pirenne F, Mégret J, Pawlotsky JM, Fillatreau S, Bruhns P, Rey FA, Weill JC, Reynaud CA, Chappert P, Mahévas M. 2021. mRNA 666 vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. 667 Immunity 54:2893-2907.e5. 668

21. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, Lundgreen KA, Reynaldi A, Khoury DS, 669 Pattekar A, Gouma S, Kuri-Cervantes L, Hicks P, Dysinger S, Hicks A, Sharma H, Herring S, Korte S, Baxter AE, Oldridge DA, 670 Giles JR, Weirick ME, McAllister CM, Awofolaju M, Tanenbaum N, Drapeau EM, Dougherty J, Long S, D'Andrea K, Hamilton 671 JT, McLaughlin M, Williams JC, Adamski S, Kuthuru O, Frank I, Betts MR, Vella LA, Grifoni A, Weiskopf D, Sette A, Hensley 672 SE, Davenport MP, Bates P, Luning Prak ET, Greenplate AR, Wherry EJ. 2021. mRNA vaccines induce durable immune memory 673 to SARS-CoV-2 and variants of concern. Science (1979) 374. 674

22. Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, Neradilek M, Seydoux E, Jennewein MF, Maccamy 675 AJ, Feng J, Mize G, De Rosa SC, Finzi A, Lemos MP, Cohen KW, Moodie Z, Mcelrath MJ, Mcguire AT. 2021. mRNA vaccination 676 boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science (1979) 372:1413. 677

23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009. Research electronic data capture (REDCap)—A 678 metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 679 42:377–381. 680

24. British Columbia Centre for Disease Control. 2021. Weekly Update on Variants of Concern. BC COVID-19 Data. Van- 681 couver. http://www.bccdc.ca/Health-Info-Site/Documents/VoC/VoC\_weekly\_09172021.pdf. Retrieved 15 September 2022. 682

25. R Core Team. 2013. R: A language and environment for statistical computing. 3.6.3-"Holding the Windsock". R Founda- 683 tion for Statistical Computing, Vienna, Austria. 684

26. Goldfarb DM, Tilley P, Al-Rawahi GN, Srigley JA, Ford G, Pedersen H, Pabbi A, Hannam-Clark S, Charles M, Dittrick 685 M, Gadkar VJ, Pernica JM, Hoanga LMN. 2021. Self-Collected Saline Gargle Samples as an Alternative to Health Care Worker- 686 Collected Nasopharyngeal Swabs for COVID-19 Diagnosis in Outpatients. J Clin Microbiol 59. 687

27. Hickman R, Nguyen J, Lee TD, Tyson JR, Azana R, Tsang F, Hoang L, Prystajecky N. 2022. Rapid, High-Throughput, 688 Cost Effective Whole Genome Sequencing of SARS-CoV-2 Using a Condensed One Hour Library Preparation of the Illumina 689 DNA Prep Kit. medRxiv 2022.02.07.22269672. 690

28. Sekirov I, Barakauskas VE, Simons J, Cook D, Bates B, Burns L, Masud S, Charles M, McLennan M, Mak A, Chahil N, 691 Vijh R, Hayden A, Goldfarb D, Levett PN, Krajden M, Morshed M. 2021. SARS-CoV-2 serology: Validation of high-throughput 692 chemiluminescent immunoassay (CLIA) platforms and a field study in British Columbia. J Clin Virol 142. 693

29. Stein DR, Osiowy C, Gretchen A, Thorlacius L, Fudge D, Lang A, Sekirov I, Morshed M, Levett PN, Tran V, Kus J v., 694 Gubbay J, Mohan V, Charlton C, Kanji JN, Tipples G, Serhir B, Therrien C, Roger M, Jiao L, Zahariadis G, Needle R, Gilbert L, 695 Desnoyers G, Garceau R, Bouhtiauy I, Longtin J, El-Gabalawy N, Dibernardo A, Lindsay LR, Drebot M. 2021. Evaluation of 696 commercial SARS-CoV-2 serological assays in Canadian public health laboratories. Diagn Microbiol Infect Dis 101. 697

30. Li FF, Liu A, Gibbs E, Tanunliong G, Marquez AC, Gantt S, Frykman H, Krajden M, Morshed M, Prystajecky NA, Cash- 698 man N, Sekirov I, Jassem AN. 2022. A novel multiplex electrochemiluminescent immunoassay for detection and quantification 699 of anti-SARS-CoV-2 IgG and anti-seasonal endemic human coronavirus IgG. J Clin Virol 146:105050. 700

31. Tanunliong G, Liu AC, Kaweski S, Irvine M, Reyes RC, Purych D, Krajden M, Morshed M, Sekirov I, Gantt S, Skowronski 701 DM, Jassem AN. 2022. Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 702 2020, British Columbia, Canada. Front Immunol 13. 703

32. Cohen J. 1992. A power primer. Psychol Bull 112:155–159. 704

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

*Viruses* **2022**, *14*, x FOR PEER REVIEW 20 of 20

